JP2016535786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535786A5 JP2016535786A5 JP2016552474A JP2016552474A JP2016535786A5 JP 2016535786 A5 JP2016535786 A5 JP 2016535786A5 JP 2016552474 A JP2016552474 A JP 2016552474A JP 2016552474 A JP2016552474 A JP 2016552474A JP 2016535786 A5 JP2016535786 A5 JP 2016535786A5
- Authority
- JP
- Japan
- Prior art keywords
- bupropion
- dextromethorphan
- composition
- administered
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MKXZASYAUGDDCJ-SZMVWBNQSA-N Dextromethorphan Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims 15
- 229960001985 Dextromethorphan Drugs 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 15
- AKOAEVOSDHIVFX-UHFFFAOYSA-N Hydroxybupropion Chemical compound OCC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 AKOAEVOSDHIVFX-UHFFFAOYSA-N 0.000 claims 12
- SNPPWIUOZRMYNY-UHFFFAOYSA-N Bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 11
- 229960001058 Bupropion Drugs 0.000 claims 11
- 230000036470 plasma concentration Effects 0.000 claims 5
- 208000009025 Nervous System Disease Diseases 0.000 claims 3
- 206010029305 Neurological disorder Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 206010058019 Cancer pain Diseases 0.000 claims 1
- 241001480079 Corymbia calophylla Species 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- XLMALTXPSGQGBX-GCJKJVERSA-N Dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 1
- 206010014551 Emotional disease Diseases 0.000 claims 1
- 206010015037 Epilepsy Diseases 0.000 claims 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 1
- 206010019233 Headache Diseases 0.000 claims 1
- 206010061284 Mental disease Diseases 0.000 claims 1
- 208000005264 Motor Neuron Disease Diseases 0.000 claims 1
- 206010028003 Motor neurone disease Diseases 0.000 claims 1
- 206010028391 Musculoskeletal pain Diseases 0.000 claims 1
- 208000004296 Neuralgia Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 206010029331 Neuropathy peripheral Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000000399 Procedural Pain Diseases 0.000 claims 1
- 229960004193 dextropropoxyphene Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 201000009457 movement disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
Claims (15)
- ブプロピオン、ヒドロキシブプロピオン、エリスロヒドロキシブプロピオン、またはトレオヒドロキシブプロピオンをデキストロメトルファンとヒトに共投与することにより、デキストロメトルファンでの治療を必要とする、デキストロメトルファンの高代謝群であるヒトにおけるデキストロメトルファンの血漿濃度を増大することにおいて使用されるデキストロメトルファンを含む組成物。
- ブプロピオン、ヒドロキシブプロピオン、エリスロヒドロキシブプロピオン、またはトレオヒドロキシブプロピオンは、少なくとも８日間連続でデキストロメトルファンと共投与される、請求項１に記載の組成物。
- ８日目に、デキストロメトルファンは、ブプロピオン、ヒドロキシブプロピオン、エリスロヒドロキシブプロピオン、またはトレオヒドロキシブプロピオンを共投与せずにデキストロメトルファンの同じ量を投与することによって達成され得る血漿濃度の少なくとも８０倍である、ブプロピオン、ヒドロキシブプロピオン、エリスロヒドロキシブプロピオン、またはトレオヒドロキシブプロピオンをデキストロメトルファンと共投与してから１２時間後の血漿濃度を有する、請求項２に記載の組成物。
- 約４０ｍｇから約１４０ｍｇのデキストロメトルファンが、１日あたり投与される、請求項１、２、または３に記載の組成物。
- 約６０ｍｇから約１００ｍｇのデキストロメトルファンが、１日あたり投与される、請求項４に記載の組成物。
- ブプロピオンは、デキストロメトルファンと共投与される、請求項１、２、３、４、または５に記載の組成物。
- 約１００ｍｇから約２５０ｍｇのブプロピオンが、１日あたり投与される、請求項６に記載の組成物。
- 約２００ｍｇから約２５０ｍｇのブプロピオンが、１日あたり投与される、請求項６に記載の組成物。
- ブプロピオンは、８日目に、ブプロピオン無しで投与されるデキストロメトルファンの同じ量の血漿濃度の少なくとも１０倍である前記ヒトにおけるデキストロメトルファンの血漿濃度をもたらす量で投与される、請求項１、２、３、４、５、６、７、または８に記載の組成物。
- ブプロピオン、ヒドロキシブプロピオン、エリスロヒドロキシブプロピオン、またはトレオヒドロキシブプロピオンは、疼痛または神経障害の治療のためにデキストロメトルファンと共投与される、請求項１、２、３、４、５、６、７、８または９に記載の組成物。
- 前記疼痛は、術後疼痛、癌性疼痛、関節痛、腰仙部の痛み、筋骨格系疼痛、中枢多発性硬化症の痛み、侵害受容性疼痛、または神経因性疼痛を含む、請求項１０に記載の組成物。
- 前記神経障害は、感情障害、精神障害、脳機能障害、運動障害、認知症、運動ニューロン疾患、神経変性疾患、発作障害、または頭痛である、請求項１０に記載の組成物。
- 前記神経障害は、うつ病である、請求項１０に記載の組成物。
- 前記神経障害は、アルツハイマー病における動揺である、請求項１０に記載の組成物。
- 前記ブプロピオン、ヒドロキシブプロピオン、エリスロヒドロキシブプロピオン、またはトレオヒドロキシブプロピオンは、単一剤形でデキストロメトルファンと共投与される、請求項１、２、３、４、５、６、７、８、９、１０、１１、１２、１３または１４に記載の組成物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019189318A JP6927601B2 (ja) | 2013-11-05 | 2019-10-16 | ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900354P | 2013-11-05 | 2013-11-05 | |
| US61/900,354 | 2013-11-05 | ||
| PCT/US2014/064184 WO2015069809A1 (en) | 2013-11-05 | 2014-11-05 | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019189318A Division JP6927601B2 (ja) | 2013-11-05 | 2019-10-16 | ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535786A JP2016535786A (ja) | 2016-11-17 |
| JP2016535786A5 true JP2016535786A5 (ja) | 2017-03-09 |
| JP6605485B2 JP6605485B2 (ja) | 2019-11-13 |
Family
ID=53042051
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552474A Active JP6605485B2 (ja) | 2013-11-05 | 2014-11-05 | ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物 |
| JP2019189318A Active JP6927601B2 (ja) | 2013-11-05 | 2019-10-16 | ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法 |
| JP2021124094A Pending JP2021169527A (ja) | 2013-11-05 | 2021-07-29 | ブプロピオンおよびデキストロメトルファンの使用 |
| JP2023122146A Pending JP2023129646A (ja) | 2013-11-05 | 2023-07-27 | ブプロピオンおよびデキストロメトルファンの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019189318A Active JP6927601B2 (ja) | 2013-11-05 | 2019-10-16 | ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法 |
| JP2021124094A Pending JP2021169527A (ja) | 2013-11-05 | 2021-07-29 | ブプロピオンおよびデキストロメトルファンの使用 |
| JP2023122146A Pending JP2023129646A (ja) | 2013-11-05 | 2023-07-27 | ブプロピオンおよびデキストロメトルファンの使用 |
Country Status (12)
| Country | Link |
|---|---|
| EP (3) | EP3981403A1 (ja) |
| JP (4) | JP6605485B2 (ja) |
| KR (4) | KR102264179B1 (ja) |
| CN (7) | CN110251517A (ja) |
| AU (6) | AU2014346807B2 (ja) |
| CA (3) | CA2929415C (ja) |
| IL (3) | IL298972A (ja) |
| MX (3) | MX2016005867A (ja) |
| MY (1) | MY179696A (ja) |
| NZ (5) | NZ758431A (ja) |
| SG (4) | SG10201911816XA (ja) |
| WO (1) | WO2015069809A1 (ja) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220233470A1 (en) | 2013-11-05 | 2022-07-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11617747B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11517543B2 (en) | 2013-11-05 | 2022-12-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11291665B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11229640B2 (en) | 2013-11-05 | 2022-01-25 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11571417B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11253492B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11419867B2 (en) | 2013-11-05 | 2022-08-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11129826B2 (en) | 2013-11-05 | 2021-09-28 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
| CN110251517A (zh) * | 2013-11-05 | 2019-09-20 | 安泰赛普生物风投二代有限责任公司 | 包含安非他酮或相关化合物和右美沙芬的组合物和方法 |
| US11197839B2 (en) | 2013-11-05 | 2021-12-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11298351B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11191739B2 (en) | 2013-11-05 | 2021-12-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11253491B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11478468B2 (en) | 2013-11-05 | 2022-10-25 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11426370B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11426401B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11439636B1 (en) | 2013-11-05 | 2022-09-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11364233B2 (en) | 2013-11-05 | 2022-06-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11576877B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as modulator of drug activity |
| US11311534B2 (en) | 2013-11-05 | 2022-04-26 | Antecip Bio Ventures Ii Llc | Bupropion as a modulator of drug activity |
| US11357744B2 (en) | 2013-11-05 | 2022-06-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11510918B2 (en) | 2013-11-05 | 2022-11-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20200338022A1 (en) | 2019-01-07 | 2020-10-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11524007B2 (en) | 2013-11-05 | 2022-12-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11207281B2 (en) | 2013-11-05 | 2021-12-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11571399B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11285118B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11382874B2 (en) | 2013-11-05 | 2022-07-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11497721B2 (en) | 2013-11-05 | 2022-11-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11590124B2 (en) | 2013-11-05 | 2023-02-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11273133B2 (en) | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11234946B2 (en) | 2013-11-05 | 2022-02-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11596627B2 (en) | 2013-11-05 | 2023-03-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11344544B2 (en) | 2013-11-05 | 2022-05-31 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11123344B2 (en) | 2013-11-05 | 2021-09-21 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
| US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11147808B2 (en) | 2013-11-05 | 2021-10-19 | Antecip Bioventures Ii Llc | Method of decreasing the fluctuation index of dextromethorphan |
| US11576909B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11298352B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11617728B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11541048B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11541021B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| CN110664801A (zh) * | 2014-09-14 | 2020-01-10 | 阿瓦尼尔制药股份有限公司 | 用于治疗痴呆中的激越行为的包含右美沙芬化合物和奎尼丁的药物组合物 |
| KR102376868B1 (ko) * | 2014-11-21 | 2022-03-18 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법 |
| EP4360628A2 (en) * | 2016-03-24 | 2024-05-01 | Antecip Bioventures II LLC | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| TWI795446B (zh) | 2017-10-04 | 2023-03-11 | 美商神經治療股份有限公司 | 右旋美索芬(dextromethorphan)經皮輸送裝置 |
| AU2020207261B2 (en) * | 2019-01-07 | 2023-04-13 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| CN115697314A (zh) * | 2020-03-30 | 2023-02-03 | 安泰赛普生物风投二代有限责任公司 | 安非他酮和右美沙芬组合用于治疗神经病症的用途 |
| CN117100750A (zh) * | 2020-07-20 | 2023-11-24 | 深圳信立泰药业股份有限公司 | 一种药物组合物及其应用 |
| JP2023553393A (ja) | 2020-12-01 | 2023-12-21 | アンテシップ バイオベンチャーズ トゥー エルエルシー | うつ病患者の自殺リスク低減のためのブプロピオンおよびデキストロメトルファン |
| KR20230131927A (ko) * | 2021-01-18 | 2023-09-14 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 신경 정신 질환에 대한 항우울제와 덱스트로메토르판의조합 |
| CN112999350A (zh) * | 2021-02-23 | 2021-06-22 | 北京斯利安药业有限公司 | 一种药物组合物、复方制剂及其制备方法与应用 |
| WO2024006853A1 (en) | 2022-06-30 | 2024-01-04 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US11844797B1 (en) | 2023-04-20 | 2023-12-19 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350756A (en) * | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
| CA2289190A1 (en) * | 1997-05-07 | 1998-11-12 | Algos Pharmaceutical Corporation | Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
| TWI326214B (en) * | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| JP2009525343A (ja) * | 2006-02-03 | 2009-07-09 | アバニール・ファーマシューティカルズ | 鬱病、不安および神経変性疾患を治療するためのデキストロメトルファンおよびキニジンを含む薬剤組成物 |
| WO2009006194A1 (en) * | 2007-06-28 | 2009-01-08 | Avanir Pharmaceuticals | Pharmaceutical compositions for the treatment of involuntary emotional expression disorder |
| WO2012118562A1 (en) | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US20130274282A1 (en) | 2012-04-16 | 2013-10-17 | Herriot Tabuteau | Compositions and methods comprising celecoxib or related compounds and dextromethorphan |
| CN110251517A (zh) * | 2013-11-05 | 2019-09-20 | 安泰赛普生物风投二代有限责任公司 | 包含安非他酮或相关化合物和右美沙芬的组合物和方法 |
-
2014
- 2014-11-05 CN CN201910649199.3A patent/CN110251517A/zh active Pending
- 2014-11-05 EP EP21191390.0A patent/EP3981403A1/en active Pending
- 2014-11-05 AU AU2014346807A patent/AU2014346807B2/en active Active
- 2014-11-05 EP EP21191393.4A patent/EP3981404A1/en active Pending
- 2014-11-05 JP JP2016552474A patent/JP6605485B2/ja active Active
- 2014-11-05 CN CN202111061009.XA patent/CN113750098A/zh active Pending
- 2014-11-05 CA CA2929415A patent/CA2929415C/en active Active
- 2014-11-05 CN CN201480072191.0A patent/CN106163522A/zh active Pending
- 2014-11-05 KR KR1020167013970A patent/KR102264179B1/ko active IP Right Grant
- 2014-11-05 SG SG10201911816XA patent/SG10201911816XA/en unknown
- 2014-11-05 SG SG10201810888XA patent/SG10201810888XA/en unknown
- 2014-11-05 IL IL298972A patent/IL298972A/en unknown
- 2014-11-05 NZ NZ758431A patent/NZ758431A/en unknown
- 2014-11-05 NZ NZ719892A patent/NZ719892A/en unknown
- 2014-11-05 MY MYPI2016701609A patent/MY179696A/en unknown
- 2014-11-05 KR KR1020227013910A patent/KR102603013B1/ko active IP Right Grant
- 2014-11-05 MX MX2016005867A patent/MX2016005867A/es active IP Right Grant
- 2014-11-05 SG SG10201911808QA patent/SG10201911808QA/en unknown
- 2014-11-05 NZ NZ758428A patent/NZ758428A/en unknown
- 2014-11-05 NZ NZ758425A patent/NZ758425A/en unknown
- 2014-11-05 CN CN201910649207.4A patent/CN110279682A/zh active Pending
- 2014-11-05 EP EP14859589.5A patent/EP3065742A4/en active Pending
- 2014-11-05 NZ NZ758432A patent/NZ758432A/en unknown
- 2014-11-05 CN CN202111061795.3A patent/CN113750099A/zh active Pending
- 2014-11-05 CN CN201910649198.9A patent/CN110327338A/zh active Pending
- 2014-11-05 CA CA3154845A patent/CA3154845C/en active Active
- 2014-11-05 KR KR1020237034772A patent/KR20230148385A/ko active Application Filing
- 2014-11-05 CA CA3175703A patent/CA3175703A1/en active Pending
- 2014-11-05 SG SG11201603391XA patent/SG11201603391XA/en unknown
- 2014-11-05 KR KR1020217016618A patent/KR20210068157A/ko active Application Filing
- 2014-11-05 WO PCT/US2014/064184 patent/WO2015069809A1/en active Application Filing
- 2014-11-05 CN CN202111061803.4A patent/CN113797205A/zh active Pending
- 2014-11-05 MX MX2020004075A patent/MX2020004075A/es unknown
-
2016
- 2016-05-04 MX MX2021015234A patent/MX2021015234A/es unknown
- 2016-05-05 IL IL245504A patent/IL245504B/en active IP Right Grant
-
2018
- 2018-05-23 AU AU2018203638A patent/AU2018203638C1/en active Active
-
2019
- 2019-09-23 AU AU2019236614A patent/AU2019236614C1/en active Active
- 2019-10-16 JP JP2019189318A patent/JP6927601B2/ja active Active
- 2019-12-04 AU AU2019275593A patent/AU2019275593B2/en active Active
-
2021
- 2021-04-23 AU AU2021202497A patent/AU2021202497B2/en active Active
- 2021-06-07 IL IL283760A patent/IL283760B2/en unknown
- 2021-07-29 JP JP2021124094A patent/JP2021169527A/ja active Pending
-
2023
- 2023-06-01 AU AU2023203438A patent/AU2023203438A1/en active Pending
- 2023-07-27 JP JP2023122146A patent/JP2023129646A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535786A5 (ja) | ||
| HRP20201855T1 (hr) | Bupropion za moduliranje razina plazme lijekova dekstrometorfana | |
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| WO2016070151A8 (en) | Methods and compositions relating to microbial treatment and diagnosis of disorders | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| EP4292588A3 (en) | Administration of deuterated cftr potentiators | |
| SG10201810888XA (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| ZA202001057B (en) | Inhibiting ubiquitin specific peptidase 30 | |
| MX355065B (es) | Método y dispositivo para conmutación de cámaras. | |
| EP4234568A3 (en) | Solid forms of berberine ursodeoxycholate and compositions and methods thereof | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| WO2014058979A8 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| CY1124115T1 (el) | Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες | |
| MX2022001565A (es) | Formas solidas de un estimulador de guanilato ciclasa soluble (sgc). | |
| WO2016168553A8 (en) | Deuterated obeticholic acid | |
| EP3309555A3 (en) | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation | |
| MX2021002012A (es) | Metodos de tratamiento del trastorno por estres agudo y trastorno por estres postraumatico. | |
| BR112017021669A2 (pt) | formulações farmacêuticas orais, método para tratar doenças e uso de ditas formulações | |
| WO2023245156A3 (en) | Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse | |
| JP2017525776A5 (ja) | ||
| WO2015165964A8 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| JP2017052778A5 (ja) | ||
| BR112018067663A2 (pt) | compostos derivados de sulfamato, processos para preparação dos mesmos e seus usos |